These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8237831)

  • 1. Implications of the ESVEM trial for use of antiarrhythmic drugs that prolong cardiac repolarization.
    Mason JW
    Am J Cardiol; 1993 Nov; 72(16):59F-61F. PubMed ID: 8237831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
    Anderson KP; Bigger JT; Freedman RA
    Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.
    Reiffel JA
    Am J Cardiol; 1996 Aug; 78(4A):34-40. PubMed ID: 8780327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring.
    Reiffel JA; Hahn E; Hartz V; Reiter MJ
    Am J Cardiol; 1997 Apr; 79(8):1048-53. PubMed ID: 9114762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias.
    Garan H
    Prog Cardiovasc Dis; 1996; 38(6):455-6. PubMed ID: 8638026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the Electrophysiology Study Versus Electrocardiographic Monitoring Trial: its programmed stimulation protocol may introduce bias when assessing long-term antiarrhythmic drug therapy.
    Biblo LA; Carlson MD; Waldo AL
    J Am Coll Cardiol; 1995 Jun; 25(7):1601-4. PubMed ID: 7759711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling cardiac arrhythmias by lengthening repolarization: historical overview.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):18F-24F. PubMed ID: 8237826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators.
    Hlatky MA; Boothroyd DB; Johnstone IM; Marcus FI; Hahn E; Hartz V; Mason JW
    J Clin Epidemiol; 1997 Feb; 50(2):185-93. PubMed ID: 9120512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
    Singh BN
    Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic agents and proarrhythmia.
    Chaudhry GM; Haffajee CI
    Crit Care Med; 2000 Oct; 28(10 Suppl):N158-64. PubMed ID: 11055685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiarrhythmic agents: current situation].
    Bonhorst D
    Rev Port Cardiol; 1995 May; 14(5):421-9, 362. PubMed ID: 7654403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.